Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03308721 | Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity | PHASE1 | COMPLETED | 99 | — | — | Oct 16, 2017 | Jan 3, 2020 | Dec 23, 2021 | 1 | United States |
Count of events
| Arm | Type | Description |
|---|---|---|
| NNC9204-1177 | EXPERIMENTAL | Dose trial with a sequential trial design |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC9204-1177 A 1.0 mg/mL | DRUG | Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks. Dose gradually increased to 6000 μg. |
| PLACEBO | DRUG | Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks. |
Inclusion Criteria: * Male or female, aged 18-55 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 27.0 and 39.9 kg/m2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator Exclusion Criteria: *...